The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
The global general anesthesia drugs market is anticipated to reach a valuation of $6.7 billion by 2032, with sales growing at a stagnant CAGR of 3.4% from 2022 to 2032, according to Future Market Insights. 12 October 2022
Swiss pharma giant Roche today announced new two-year data showing that its Evrysdi (risdiplam) improved or maintained motor function in people with spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatal. 12 October 2022
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy). 11 October 2022
Results from early stage research into AstraZeneca’s coronavirus vaccine has poured cold water onto hopes that a nasally-administered form of the jab could be developed soon. 11 October 2022
Reports hinting that Michelle McMurry-Heath’s days as president and chief executive of the Biotechnology Innovation Organization (BIO) might be numbered have circulated in recent days. 11 October 2022
Shares of Ginkgo Bioworks were down 3.6% at $2.78 today, despite the company announcing a deal with US pharma giant Merck & Co to engineer a crucial component of up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts. 11 October 2022
Oxford, UK-based start-up Ochre Bio, an innovator in chronic liver disease drug development, yesterday announced the successful close of $30 million in Series A financing. 11 October 2022
Neumora Therapeutics, a US clinical-stage biotech focussed on brain diseases through the integration of data science and neuroscience that came out of stealth in July last year with $500 million financing, has added to its cash pile announcing today the close of a $112 million Series B financing. 11 October 2022
The UK’s BioIndustry Association (BIA), the trade body for innovative life sciences, has welcomed a one-year extension to the European Commission Decision Reliance Procedure (ECDRP). 11 October 2022
German pharma major Bayer had a boost for its Kerendia (finerenone), a non-steroidal mineralocorticoid receptor antagonist, with an important endorsement for the drug’s use. 11 October 2022
Positive Phase III trial results evaluating the investigational use of Dupixent (dupilumab) in children aged one to 11 years with active eosinophilic esophagitis (EoE) were presented today at United European Gastroenterology (UEG) Week 2022. 11 October 2022
Singapore-based TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, recently reported positive progress for the firm's lead investigative oral drug hydromethylthionine mesylate (HMTM). The drug was found to be effective in improving cognition in patients with early Alzheimer’s disease (AD). 11 October 2022
The European Commission has informed Israel-based generics behemoth Teva Pharmaceutical Industries of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate). 10 October 2022
Swedish firm InDex Pharmaceuticals has announced that its board of directors has named Jenny Sundqvist as the company's new chief executive. 10 October 2022
In what could be a paradigm shift in the treatment of congestion due to worsening heart failure, the US Food and Drug Administration (FDA) has approved Furoscix (furosemide injection). 10 October 2022
Privately-held Covis Pharma knows what it is up against from the US Food and Drug Administration (FDA) as the regulator attempts to have the company’s preterm birth (PTB) drug Makena (hydroxyprogesterone caproate) withdrawn from the market. 10 October 2022
Set against a turbulent economic backdrop, a major fundraise from the life sciences division of Andera Partners shows there is still significant appetite for investment in the biotech sector. 10 October 2022